Microbiopsy Market's Projected Worth Reaches US$ 305.7 Million by 2033

The microbiopsy market is anticipated to reach a valuation of US$ 157.5 million by 2023. It is anticipated that the market will grow at a 6.9% CAGR to reach US$ 305.7 million by 2033. The phrase "microbiopsy market" refers to the worldwide market for microbiopsy instruments, materials, and services. A microbiopsy is a minimally invasive procedure used to obtain small tissue samples for use in research, diagnosis, or therapy. The treatment is widely used in many medical specialties, including urology, dermatology, oncology, and gastrointestinal disorders.

Numerous reasons have contributed to the tremendous rise of the microbiopsy market in recent years. These include the rise in the incidence of chronic illnesses like cancer, the demand for less intrusive procedures, the development of microbiopsy equipment, and the increased emphasis on personalized medicine. The market's progress has also been aided by the increase of RD activities and the increasing use of microbiopsy procedures in research organizations, pharmaceutical firms, and academic institutions.

Achieve Peak Productivity - Don't Delay Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17647

In general, it is anticipated that the microbiopsy industry would keep expanding in the upcoming years. The market is projected to grow as a result of factors like the rising prevalence of chronic diseases, improvements in microbiopsy technology, and the demand for precise and individualized diagnosis and treatments.

Key Takeaways:

The microbiopsy industry in the United States is predicted to reach US$ 96.3 million by 2033, increasing at a 6.4% CAGR.
The microbiopsy industry in the United Kingdom is estimated to reach a market value of US$ 15.6 million, expanding at a CAGR of 6.3% by 2033.
During the forecast period, the microbiopsy industry in China is expected to reach a market value of US$ 18.7 million, securing an 8.1% CAGR over the forecast period.
The microbiopsy industry in Japan is predicted to reach US$ 15.2 million by 2033, increasing at a 7.4% CAGR.
South Korea's microbiopsy industry is predicted to achieve a market value of US$ 13.5 million, rising at an 8.8% CAGR by 2033 end.
With a CAGR of 8.2% from 2023 to 2033, microbiopsy needles segment is expected to dominate the microbiopsy industry.
With a CAGR of 8.2% from 2023 to 2033, the skin cancer indication are expected to dominate the microbiopsy industry.
With a CAGR of 6.7% from 2023 to 2033, the hospitals are expected to dominate the microbiopsy industry.

Key Players:

Trajan Scientific Australia Pty Ltd.
Vigeo
Zamar Biopsy
Medax
AprioMed
Hologic
Mammotome
M.D.L.
Histo
Changzhou Mingle Medical Equipment Co., Ltd.
Surtex Instruments Limited
STERIS
MICRO-TECH EUROPE
Boston Scientific Corporation

Key Developments:

In April 2022, Together with scientists from The University of Queensland (UQ), Trajan Scientific and Medical (Trajan, ASX:TRJ) created a portable skin microbiopsy equipment that collects tissue samples with a diameter of less than 0.5 mm. The instrument is made to gather biopsies for disorders of the skin, including skin cancer.
In January 2021, A market leader in women's health, Hologic, Inc. (Nasdaq: HOLX), has announced that it has reached an agreement to purchase privately held, commercial-stage startup Biotheranostics, Inc., which offers molecular diagnostic tests for breast and metastatic cancers.

Segmentation Analysis of the Microbiopsy Market

By Product: